Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy
International Journal of Urology · 2024
DOI: 10.1111/iju.15579 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2024. Verfasst von Takanari Kambe und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Estramustine, Prostatectomy, Prostatic Neoplasms, Robotic Surgical Procedures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Objectives
The objective of this study is to evaluate the safety and efficacy of neoadjuvant degarelix acetate and low‐dose estramustine phosphate for high−/very high‐risk prostate cancer.
Methods
Overall, 187 patients diagnosed with National Comprehensive Cancer Network high−/very high‐risk cTanyN0M0 localized prostate cancer who consented to undergo robot‐assisted radical prostatectomy after receiving neoadjuvant chemohormonal therapy for 6 months were prospectively enrolled between December 2017 and March 2023. Adverse events, perioperative and histopathological outcomes, and biochemical recurrence‐free survival rates were examined. Survival analysis compared the estramustine phosphate completion and reduction groups.
Results
Thirty‐six patients discontinued neoadjuvant therapy in
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan.
ORCID-Profile: Takanari Kambe, Hiroki Hagimoto, Yuto Hattori
Zitieren
APA
Kambe, T., Yamasaki, T., Yamamoto, A., Nagoshi, A., Fujiwara, T., Mine, Y., Hagimoto, H., Igarashi, A., Kokubun, H., Murata, S., Akagi, N., Hattori, Y., Abe, Y., Tsutsumi, N., Shibasaki, N., & Kawakita, M. (2024). Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy. International Journal of Urology. https://doi.org/10.1111/iju.15579
Vancouver
Kambe T, Yamasaki T, Yamamoto A, Nagoshi A, Fujiwara T, Mine Y, et al. Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy. International Journal of Urology. 2024. doi:10.1111/iju.15579
BibTeX
@article{Kambe2024,
author = {Kambe, Takanari and Yamasaki, Toshinari and Yamamoto, Akihiro and Nagoshi, Akihiko and Fujiwara, Tasuku and Mine, Yuta and Hagimoto, Hiroki and Igarashi, Atsushi and Kokubun, Hidetoshi and Murata, Shiori and Akagi, Naoki and Hattori, Yuto and Abe, Yohei and Tsutsumi, Naofumi and Shibasaki, Noboru and Kawakita, Mutsushi},
title = {Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy},
journal = {International Journal of Urology},
year = {2024},
doi = {10.1111/iju.15579}
}
EUVIMED